Ultralow doses of various drugs in chemotherapy of experimental tumors.
Antitumor activity of ultralow doses of cytostatic lonidamine and effects of various biological preparations in ultralow doses (chemosensitizer, immunomodulator, and antioxidant) on the efficiency of adriamycin and cisplatin were studied in animals with transplanted tumors. High efficiency of this method was demonstrated. Nitrotriazole chemosensitizer in ultralow doses increased the sensitivity of leukemia P388/rn substrain with multiple drug resistance phenotype to mitomycin C during combination therapy.
Konovalova
N P
NP
Institute of Problems in Chemical Physics, Russian Academy of Sciences.
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols; D002945:Cisplatin / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004317:Doxorubicin / Q000627:therapeutic use; D018432:Drug Resistance, Multiple / Q000187:drug effects; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D007191:Indazoles / Q000627:therapeutic use; D007941:Leukemia P388 / Q000188:drug therapy; D008175:Lung Neoplasms / Q000188:drug therapy; D008545:Melanoma / Q000188:drug therapy; D051379:Mice; D016685:Mitomycin / Q000627:therapeutic use; D009362:Neoplasm Metastasis / Q000188:drug therapy; D009374:Neoplasms, Experimental / Q000188:drug therapy*; D014230:Triazoles / Q000627:therapeutic use; D023041:Xenograft Model Antitumor Assays
D000970:Antineoplastic Agents; D007191:Indazoles; D014230:Triazoles; C072690:AK 2123; D016685:Mitomycin; D004317:Doxorubicin; D002945:Cisplatin; C016371:lonidamine